<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813306</url>
  </required_header>
  <id_info>
    <org_study_id>D9126C00001</org_study_id>
    <nct_id>NCT00813306</nct_id>
  </id_info>
  <brief_title>14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Single-centre Phase I Pharmacodynamic Cross-over Study to Assess the Effect of a Single Dose of AZD2066 Oral Solution in Comparison to Placebo on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and tolerability of AZD2066 and to explore
      the effect of a single dose of AZD2066 on the function of the cardia (the opening between the
      stomach and the esophagus) compared to placebo (not containing any medical substance) in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Manometry</measure>
    <time_frame>3.45 hours each study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>3.45 hours each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impedance</measure>
    <time_frame>3.45 hours each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables</measure>
    <time_frame>3.45 hours each study period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Reflux Episodes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2066</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2066</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2066</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>13 mg oral solution, 1 single dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution, 1 single dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution, 1 single dose</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written consent prior to any study specific procedures.

          -  Healthy subjects, age 18-45 years inclusive. Females must be of no childbearing
             potential or must use a highly effective contraceptive method.

          -  Clinically normal physical findings and laboratory values at the time of pre-entry
             visit, as judged by the investigator.

        Exclusion Criteria:

          -  Clinically significant illness within the 2 weeks prior to the first dose of the
             investigational product, including a suspected/manifested infection according to WHO
             risk categories 2, 3 or 4, as judged by the investigator.

          -  A measured LES pressure of &lt; 5mm Hg.

          -  History of previous or ongoing psychiatric disease/condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Sundin</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D MÃ¶lndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy E Boeckxstaens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Motiliteitscentrum (C2-310)Department of Gastroenterology,Academic Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>December 6, 2010</last_update_submitted>
  <last_update_submitted_qc>December 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mark Berner-Hansen, MD, PhDMedical Science Director, Early GI</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>TLESR</keyword>
  <keyword>reflux</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

